Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia

International Journal of Hematology

Volumn 102, Issue 5, 2015, Pages 579-586

  Sun, Hui ^a   Li, Yi ^a   Zhang, Zhi fen ^a   Ju, Ying ^a   Li, Li ^a   Zhang, Bing chang ^a   Liu, Bin ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Adult acute myeloid leukemia (AML); Immune suppression; Minimal residual disease (MRD); Myeloid derived suppressor cells (MDSCs)

Indexed keywords

CD11B ANTIGEN; CD33 ANTIGEN; D DIMER; HLA DR ANTIGEN; PROTEIN; UNCLASSIFIED DRUG; WILM TUMOR 1 PROTEIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FUSION GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; SUPPRESSOR CELL; BLOOD; BONE MARROW CELL; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR ESCAPE;

ADULT; BONE MARROW CELLS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MONOCYTES; NEOPLASM, RESIDUAL; PROGNOSIS; TUMOR ESCAPE; WT1 PROTEINS;

EID: 84947019501     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1865-2     Document Type: Article

References (20)

1. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099–107.
2. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ et al. SEER Cancer Statistics Review. 1975–2005. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2005/. Accessed 23 May 2015
3. Zhao X, Rong L, Zhao X, Li X, Liu X, Deng J, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012;122:4094–104.
4. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190:3783–97.
5. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14 + HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70:4335–45.
6. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012;61:255–63.
7. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.
8. Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121:2975–87.
9. Liu J, Zhou Y, Huang Q, Qiu L. CD14HLA-DR expression: a novel prognostic factor in chronic lymphocytic leukemia. Oncol Lett. 2015;9:1167–72.
10. Zhang ZN, Shen T. Diagnosis and curative effect standard of blood disease. 3rd ed. Beijing: Science Press; 2007. p. 116–21.
11. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13:721s–6s.
12. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678–89.
13. Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T, et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol. 2013;190:3815–23.
14. Jitschin R, Braun M, Buttner M, Dettmer-Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14 + HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750–60.
15. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14 + HLA-DR(low)/− monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011;117:872–81.
16. Wei X, Xu YD, HE J. Clinical significance of plasma D-dimer measurement in acute leukemia patients. J China Med Univ. 2011;V40:343.
17. Gustafson MP, Abraham RS, Lin Y, Wu W, Gastineau DA, Zent CS, et al. Association of an increased frequency of CD14 + HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol. 2012;156:674–6.
18. Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee JH, et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 2007;13:4840–8.
19. Kusmartsev S, Eruslanov E, Kubler H, Tseng T, Sakai Y, Su Z et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008;181:346–53.
20. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49–59.